Dr. Robin Downing podcast spotlights practical OA pain strategies
A new Clinician’s Brief partner podcast puts canine and feline osteoarthritis pain management back in focus, with pain specialist Dr. Robin Downing discussing practical treatment strategies that go beyond a single-drug approach. The episode, sponsored by PRN Pharmacal, centers on recognizing pain and inflammation earlier, building more complete analgesic plans, and improving conversations with pet parents about quality of life and function. That arrives as osteoarthritis care continues to evolve, with current AAHA pain management guidance emphasizing regular reassessment, multimodal treatment, and validated tools such as the Canine Brief Pain Inventory and LOAD questionnaires rather than a reactive, one-and-done prescribing model. Related Clinician’s Brief podcast coverage has reinforced that mobility and joint health discussions should extend beyond medications and supplements alone, with sports medicine and rehab specialist Dr. Matt Brunke highlighting obesity, inactivity, rehabilitation, and day-to-day function as central parts of joint care in both dogs and cats. (cliniciansbrief.com)
Why it matters: For veterinary professionals, the timing is notable because OA pain management is getting more complex, not less. NSAIDs remain a mainstay, but the treatment landscape now also includes anti-NGF monoclonal antibodies such as bedinvetmab, physical rehabilitation, weight management, and structured monitoring over time. That broader mobility picture matters in cats as well as dogs: Brunke noted that many indoor cats are overweight, can develop primary osteoarthritis with age, and may show reduced mobility in subtle ways that are easy to miss without asking owners about jumping, stairs, and activity at home. A 2025 Frontiers in Veterinary Science study comparing bedinvetmab with meloxicam found similar pain-control efficacy over 56 days, with fewer reported adverse events in the bedinvetmab group, while FDA safety-related labeling changes for Librela in February 2025 added stronger client communication requirements and post-approval adverse-event information. For clinicians, that means case selection, expectation-setting, environmental and lifestyle management, and follow-up are increasingly central to OA care. (frontiersin.org)
What to watch: Expect continued discussion around how practices balance multimodal OA protocols, rehab and weight-management strategies, pet parent counseling, and safety monitoring as newer analgesic options gain wider use. (fda.gov)